ATFB
MCID: FML001
MIFTS: 67

Familial Atrial Fibrillation (ATFB)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Rare diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Familial Atrial Fibrillation

MalaCards integrated aliases for Familial Atrial Fibrillation:

Name: Familial Atrial Fibrillation 11 19 42 58 28 5 14 71 75
Atrial Fibrillation, Familial 19 42 53
Atfb 11 19
Atrial Fibrillation Autosomal Dominant 19
Autosomal Dominant Atrial Fibrillation 19
Atrial Fibrillation, Familial, 1 71
Auricular Fibrillation 42
Atrial Fibrillation 71

Characteristics:


Inheritance:

Autosomal dominant 58

Classifications:



External Ids:

Disease Ontology 11 DOID:0050650
ICD10 via Orphanet 32 I48.9
Orphanet 58 ORPHA334
UMLS 71 C0004238 C1843687 C3468561

Summaries for Familial Atrial Fibrillation

GARD: 19 Familial atrial fibrillation is an inherited heart condition that disrupts the heart's rhythm. It is characterized by erratic electrical activity in the heart's upper chambers (the atria), causing an irregular response in the heart's lower chambers (the ventricles). This causes a fast and irregular heartbeat (arrhythmia). Symptoms may include dizziness, chest pain, palpitations, shortness of breath, or fainting. The disease also causes an increased risk of stroke.. While complications may occur at any age, some people never have associated health problems. Familial atrial fibrillation may be caused by changes in any of various genes, some of which have not been identified. It is most often inherited in an autosomal dominant manner, but autosomal recessive inheritance has been reported.

MalaCards based summary: Familial Atrial Fibrillation, also known as atrial fibrillation, familial, is related to atrial fibrillation and long qt syndrome, and has symptoms including angina pectoris, chest pain and edema. An important gene associated with Familial Atrial Fibrillation is MYL4 (Myosin Light Chain 4), and among its related pathways/superpathways are Cardiac conduction and G-Beta Gamma Signaling. The drugs Hydroxychloroquine and Ranolazine have been mentioned in the context of this disorder. Affiliated tissues include heart, atrioventricular node and brain, and related phenotypes are muscle and cardiovascular system

MedlinePlus Genetics: 42 Familial atrial fibrillation is an inherited abnormality of the heart's normal rhythm. Atrial fibrillation is characterized by episodes of uncoordinated electrical activity (fibrillation) in the heart's upper chambers (the atria), which cause a fast and irregular heartbeat. If untreated, this abnormal heart rhythm (arrhythmia) can lead to dizziness, chest pain, a sensation of fluttering or pounding in the chest (palpitations), shortness of breath, or fainting (syncope). Atrial fibrillation also increases the risk of stroke and sudden death. Complications of atrial fibrillation can occur at any age, although some people with this heart condition never experience any health problems associated with the disorder.

Orphanet: 58 Familial atrial fibrillation is a rare, genetically heterogenous cardiac disease characterized by erratic activation of the atria with an irregular ventricular response, in various members of a single family. It may be asymptomatic or associated with palpitations, dyspnea and light-headedness. Concomitant rhythm disorders and cardiomyopathies are frequently reported.

Disease Ontology: 11 An atrial fibrillation that has material basis in autosomal dominant inheritance of the familial atrial fibrillation (ATFB) genes.

Wikipedia: 75 Familial atrial fibrillation is an autosomal dominant heart condition that causes disruptions in the... more...

Related Diseases for Familial Atrial Fibrillation

Diseases in the Atrial Fibrillation family:

Atrial Fibrillation, Familial, 3 Atrial Fibrillation, Familial, 1
Atrial Fibrillation, Familial, 2 Atrial Fibrillation, Familial, 4
Atrial Fibrillation, Familial, 5 Atrial Fibrillation, Familial, 6
Atrial Fibrillation, Familial, 7 Atrial Fibrillation, Familial, 8
Atrial Fibrillation, Familial, 9 Atrial Fibrillation, Familial, 10
Atrial Fibrillation, Familial, 11 Atrial Fibrillation, Familial, 12
Atrial Fibrillation, Familial, 13 Atrial Fibrillation, Familial, 14
Atrial Fibrillation, Familial, 15 Atrial Fibrillation, Familial, 18
Familial Atrial Fibrillation

Diseases related to Familial Atrial Fibrillation via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 183)
# Related Disease Score Top Affiliating Genes
1 atrial fibrillation 31.9 SCN5A SCN4B SCN3B SCN2B PITX2 NUP155
2 long qt syndrome 31.3 SCN5A SCN4B SCN3B SCN2B NKX2-5 KCNQ1
3 ventricular fibrillation, paroxysmal familial, 1 31.1 SCN5A KCNQ1 KCNE2
4 sick sinus syndrome 31.1 SCN5A SCN3B NPPA GJA5
5 third-degree atrioventricular block 31.0 SCN5A NUP155 NKX2-5 KCNQ1 KCNJ2 KCNE2
6 brugada syndrome 31.0 SCN5A SCN4B SCN3B SCN2B PITX2 NUP155
7 long qt syndrome 1 30.9 SCN5A SCN4B SCN3B SCN2B NKX2-5 KCNQ1
8 congestive heart failure 30.9 SCN5A NPPA KCNQ1 KCNJ2 KCNE2 GATA4
9 dilated cardiomyopathy 30.9 SCN5A SCN4B SCN3B NPPA NKX2-5 MYL4
10 progressive familial heart block 30.8 SCN5A KCNQ1 GJA5
11 long qt syndrome 6 30.7 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
12 short qt syndrome 30.7 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
13 atrioventricular block 30.7 SCN5A NKX2-5 KCNQ1 KCNJ2 KCNE2 GJA5
14 long qt syndrome 10 30.7 SCN5A SCN4B KCNJ2 KCNE2
15 jervell and lange-nielsen syndrome 1 30.7 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
16 syncope 30.7 SCN5A NPPA KCNQ1
17 wolff-parkinson-white syndrome 30.7 SCN5A NKX2-5 KCNQ1 GJA5
18 patent ductus arteriosus 1 30.7 PITX2 NKX2-5 GATA6 GATA5 GATA4
19 cardiac conduction defect 30.7 SCN5A KCNQ1
20 atrial fibrillation, familial, 1 30.6 PITX2 ATFB1
21 progressive familial heart block, type ia 30.6 SCN5A GJA5
22 ebstein anomaly 30.6 SCN5A NKX2-5 GJA5 GATA4
23 heart septal defect 30.6 PITX2 NPPA NKX2-5 GJA5 GATA6 GATA5
24 atrial heart septal defect 30.6 SCN5A PITX2 NPPA NKX2-5 GJA5 GATA6
25 aortic valve disease 1 30.5 NKX2-5 KCNJ2 GATA6 GATA5 GATA4
26 atrial fibrillation, familial, 15 11.6
27 brugada syndrome 7 11.6
28 atrial fibrillation, familial, 11 11.2
29 atrial fibrillation, familial, 12 11.2
30 atrial fibrillation, familial, 13 11.2
31 atrial fibrillation, familial, 14 11.2
32 mitral valve stenosis 10.6
33 long qt syndrome 12 10.5 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
34 long qt syndrome 13 10.5 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
35 sinoatrial node disease 10.5 SCN5A SCN3B NKX2-5 KCNQ1 KCNJ2 KCNE2
36 long qt syndrome 5 10.5 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
37 long qt syndrome 9 10.5 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
38 long qt syndrome 2 10.5 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
39 long qt syndrome 3 10.5 SCN5A SCN4B SCN3B KCNQ1 KCNJ2 KCNE2
40 timothy syndrome 10.5 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
41 andersen cardiodysrhythmic periodic paralysis 10.5 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
42 long qt syndrome 14 10.5 SCN5A SCN4B KCNQ1 KCNJ2
43 cardiac arrhythmia, ankyrin-b-related 10.5 SCN5A SCN4B KCNQ1 KCNJ2 KCNE2
44 long qt syndrome 11 10.5 SCN4B KCNQ1 KCNJ2 KCNE2
45 brugada syndrome 4 10.5 SCN5A KCNQ1 KCNJ2
46 first-degree atrioventricular block 10.5 SCN5A KCNJ2 GJA5
47 atrial standstill 10.5 SCN5A NPPA GJA5
48 catecholaminergic polymorphic ventricular tachycardia 10.5 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
49 hypokalemic periodic paralysis, type 1 10.5 SCN5A SCN4B KCNQ1 KCNJ2
50 intrinsic cardiomyopathy 10.5 SCN5A SCN4B NPPA NKX2-5 KCNQ1 KCNJ2

Comorbidity relations with Familial Atrial Fibrillation via Phenotypic Disease Network (PDN): (show top 50) (show all 174)


Accessory Nerve Disease Acquired Polycythemia
Acquired Thrombocytopenia Active Peptic Ulcer Disease
Acute Conjunctivitis Acute Cor Pulmonale
Acute Cystitis Acute Kidney Failure
Acute Myocardial Infarction Acute Vascular Insufficiency of Intestine
Alcohol Use Disorder Alcoholic Cardiomyopathy
Alcoholic Liver Cirrhosis Amyloidosis
Anemia, Autoimmune Hemolytic Anthracosis
Anxiety Aortic Aneurysm
Aortic Atherosclerosis Aortic Valve Disease 1
Aortic Valve Disease 2 Aortic Valve Insufficiency
Asbestosis Asthma
Atrial Tachyarrhythmia with Short Pr Interval Atrioventricular Block
Bacteremia 2 Basilar Artery Insufficiency
Benign Essential Hypertension Bleeding Disorder, Platelet-Type, 11
Blepharitis Bronchiectasis
Bronchitis Bronchopneumonia
Candidiasis Cardiac Arrest
Cardiogenic Shock Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Cholangitis Cholecystitis
Chronic Intestinal Vascular Insufficiency Chronic Kidney Disease
Chronic Pulmonary Heart Disease Chronic Rheumatic Pericarditis
Chronic Ulcer of Skin Colorectal Cancer
Conjunctivitis Constrictive Pericarditis

Graphical network of the top 20 diseases related to Familial Atrial Fibrillation:



Diseases related to Familial Atrial Fibrillation

Symptoms & Phenotypes for Familial Atrial Fibrillation

UMLS symptoms related to Familial Atrial Fibrillation:


angina pectoris; chest pain; edema

MGI Mouse Phenotypes related to Familial Atrial Fibrillation:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 10.03 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNJ2
2 cardiovascular system MP:0005385 9.8 GATA4 GATA5 GATA6 GJA5 KCNA5 KCNJ2
3 digestive/alimentary MP:0005381 9.76 GATA4 GATA5 GJA5 KCNE2 KCNJ2 KCNQ1
4 respiratory system MP:0005388 9.17 GATA4 GATA6 GJA5 KCNJ2 NKX2-5 PITX2

Drugs & Therapeutics for Familial Atrial Fibrillation

Drugs for Familial Atrial Fibrillation (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 379)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Hydroxychloroquine Approved Phase 4 118-42-3 3652
2
Ranolazine Approved, Investigational Phase 4 142387-99-3, 95635-55-5 56959
3
Bivalirudin Approved, Investigational Phase 4 128270-60-0 19797045 16129704
4
Canrenoic acid Approved, Withdrawn Phase 4 4138-96-9 4872
5
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
6
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
7
Carbamide peroxide Approved Phase 4 124-43-6
8
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
9
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
10
Bisoprolol Approved Phase 4 66722-44-9 2405
11
Adenosine Approved, Investigational Phase 4 58-61-7 60961
12
Nifedipine Approved Phase 4 21829-25-4 4485
13
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
14
Ibutilide Approved Phase 4 122647-32-9, 122647-31-8 60753
15
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
16
Acenocoumarol Approved, Investigational Phase 4 152-72-7 54676537 9052
17
Phenindione Approved, Investigational Phase 4 83-12-5 4760
18
Procainamide Approved Phase 4 51-06-9 4913
19
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
20
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
21
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
22
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
23
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
24
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
25
Fluindione Approved, Investigational Phase 4 957-56-2
26
Ezetimibe Approved Phase 4 163222-33-1 150311
27
Nebivolol Approved, Investigational Phase 4 152520-56-4, 99200-09-6, 118457-14-0 71301
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3 3680
29
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 3003 5743
30
Atenolol Approved Phase 4 29122-68-7 2249
31
Acetaminophen Approved Phase 4 103-90-2 1983
32
Antazoline Approved Phase 4 91-75-8 2200
33
Histamine Approved, Investigational Phase 4 51-45-6 774
34
Pantoprazole Approved Phase 4 102625-70-7, 138786-67-1 4679
35
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
36
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
37
Ajmaline Approved, Experimental Phase 4 4360-12-7 441080
38
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
39
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
40
Quinapril Approved, Investigational Phase 4 82586-55-8, 85441-61-8 54892
41
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
42
Terazosin Approved Phase 4 63590-64-7 5401
43
Rabeprazole Approved, Investigational Phase 4 117976-89-3, 117976-90-6 5029
44
Methohexital Approved Phase 4 151-83-7 9034
45
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
46
Clavulanic acid Approved, Vet_approved Phase 4 58001-44-8 5280980
47
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560
48
Ketoconazole Approved, Investigational Phase 4 65277-42-1, 142128-57-2 47576 3823 638701
49
Amlodipine Approved Phase 4 88150-42-9 2162
50
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754

Interventional clinical trials:

(show top 50) (show all 2955)
# Name Status NCT ID Phase Drugs
1 Effect of Hydroxychloroquine on Atrial Fibrillation Recurrence After Radiofrequency Catheter Ablation in Patients With Atrial Fibrillation Unknown status NCT03592823 Phase 4 Hydroxychloroquine Sulfate 200 Mg Tablet
2 Atrial Fibrillation and Pericardial Drainage: Incidence of Postoperative Atrial Fibrillation According to the Type of Mediastinal Drainage Catheters Unknown status NCT02808897 Phase 4
3 Improved Exercise Tolerance in Participants With PReserved Ejection Fraction by Spironolactone on Myocardial Fibrosis in Atrial Fibrillation Unknown status NCT02673463 Phase 4 Spironolactone;Placebo
4 Phenprocoumon Versus Dabigatran in Subjects With Atrial Fibrillation and Left Atrial Thrombus - a Prospective, Randomized, Controlled, Open-label One Year Follow-up Pilot Study Unknown status NCT02591225 Phase 4 Dabigatranetexilate;Phenprocoumon
5 Amiodarone Prophylaxis for Atrial Fibrillation in Patients Undergoing Surgery for Lung Cancer: A Controlled, Randomized, Double Blinded Trial Unknown status NCT00724581 Phase 4 Amiodarone
6 Antiarrhythmic Drugs Assessment in Preventing Atrial Fibrillation Unknown status NCT02145546 Phase 4 Amiodarone;Propafenone;Sotalol
7 Comparison of Efficacy and Safety of Different Doses of Nifekalant Instant Cardioversion of Persistent Atrial Fibrillation During Radiofrequency Ablation:a Single-center Randomized Controlled Trial Unknown status NCT04209959 Phase 4 nifekalant
8 Rate Control in Atrial Fibrillation: A Randomized, Double-Blind, Crossover Comparison of Carvedilol and Metoprolol Tartrate Unknown status NCT02251509 Phase 4 Carvedilol;Metoprolol tartrate
9 Left Atrial Ablation for Paroxysmal Atrial Fibrillation and Hypertension With Implantable Loop Recorder With or Without ROX Coupler Follow Up Study: The LAAPITUP 3 Study Unknown status NCT02243891 Phase 4
10 Comparison of Efficacy and Safety Among DAbigatran, RIvaroxaban, and ApixabaN in Patients HavinG Non-Valvular Atrial Fibrillation in Taiwan (DARING-AF Study) Unknown status NCT02666157 Phase 4 Dabigatran etexilate;Rivaroxaban;Apixaban
11 Safety and Efficacy of Transvenous Pulmonary Isolation for the Treatment of Atrial Fibrillation: A Prospective Randomized Study Comparing Radiofrequency Energy With Cryoenergy Unknown status NCT00773539 Phase 4
12 Comparison of Two Strategies for the Management of Atrial Fibrillation After Cardiac Surgery : a Randomized Multicenter Clinical Trial Unknown status NCT04223739 Phase 4 Landiolol;Amiodarone
13 Impact of Colchicine Therapy on Arrhythmia Recurrence After Acute Pericardial Effusion Following Catheter Ablation of Atrial Fibrillation Unknown status NCT02260206 Phase 4 Colchicine
14 Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study) Unknown status NCT02642419 Phase 4 Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
15 Comparison of a Rhythm Control Treatment Strategy Versus a Rate Control Strategy in Patients With Permanent or Long-term Persistent Atrial Fibrillation and Heart Failure Treated With Cardiac Resynchronization Therapy - a Pilot Study Unknown status NCT01850277 Phase 4 Amiodarone;Pharmacotherapy to slow and control ventricular rate
16 Multi-center Application of Bivalirudin in High-risk Bleeding Patients With Non-valvular Atrial Fibrillation Undergoing Percutaneous Left Atrial Appendage Occlusion Unknown status NCT04195997 Phase 4 Bivalirudin;Heparin
17 Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control Unknown status NCT02025465 Phase 4 Metoprolol;Diltiazem
18 N-3 Fatty Acids for the Prevention of Atrial Fibrillation in Patients With Acute Heart Failure Unknown status NCT00692718 Phase 4 Epadel, Eicosapentaenoic acid
19 Gradual Diltiazem Infusion as an Approach to Initial Rate Control in Atrial Fibrillation or Atrial Flutter With Rapid Ventricular Response in the Emergency Setting Unknown status NCT04141553 Phase 4 Diltiazem Injection
20 Detection of Silent Atrial Fibrillation aFter Ischemic StrOke (SAFFO) Guided by Implantable Loop Recorder. Multicentre Italian Trial Based on Stroke Unit Network With Paired Cardio-Arrhythmology Units (Italian Neurocardiology Unit Network) Unknown status NCT02684825 Phase 4
21 A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor Unknown status NCT02639793 Phase 4
22 The Efficacy and Safety of Dabigatran Etexilate and Different Intensity Warfarin for the Prevention of Stroke and Systemic Embolism in Patients With Non-valvular Atrial Fibrillation Unknown status NCT02646267 Phase 4 standard intensity warfarin;low intensity warfarin;dabigatran etexilate
23 Intensive Statin Therapy Effect on Incidence of Post-Operative Atrial Fibrillation Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
24 A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure Unknown status NCT03088072 Phase 4 Edoxaban;Aspirin and Clopidogrel;Aspirin and Warfarin
25 Rapid Atrial Fibrillation Treatment Strategy Unknown status NCT04092621 Phase 4 Amiodarone in Parenteral Dosage Form;Amiodarone Pill;Rate-control therapy
26 Low Dose of Diltiazem for Rate Control of Atrial Fibrillation Unknown status NCT00834925 Phase 4 low dose diltiazem
27 Effects of Vernakalant and Flecainide on Atrial Contractility in Patients With Atrial Fibrillation Unknown status NCT01646281 Phase 4 Vernakalant;Flecainide
28 Rivaroxaban in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention Unknown status NCT02334254 Phase 4 rivaroxaban and ticagrel therapy;triple antithrombotic regimen with warfarin, asipirin and clopidogrel
29 Clinical Efficacy of Potassium Canrenoate - Canrenone in Sinus Rhythm Restoration Among Patients With Atrial Fibrillation and Elevated Blood Pressure - a Pilot Randomized Controlled Trial. Unknown status NCT03536806 Phase 4 Saline 0.9%;Canrenone
30 A Prospective, Multi-Center, Pilot Study to Compare the Safety and Effectiveness of WATCHMAN Left Atrial Appendage Occlusion Device With Rivaroxaban for Stroke Prevention in Patients With Atrial Fibrillation Unknown status NCT02549963 Phase 4 Rivaroxaban
31 Atrial Fibrillation Ablation Compared to Rate Control Strategy in Patients With Recently Diagnosed Impaired Left Ventricular Function: a Multicenter, Randomized Controlled Trial Unknown status NCT02509754 Phase 4
32 An Open-label, Randomized, Controlled, Multicenter Study to Evaluate DUAL Antithrombotic Therapy With Rivaroxaban Plus Ticagrelor vs. Rivaroxaban Plus Clopidogrel in Patients With Atrial Fibrillation and Acute Coronary Syndrome Unknown status NCT04023630 Phase 4 Rivaroxaban 15 MG Oral Tablet;Clopidogrel 75 Mg Oral Tablet;Ticagrelor 90 MG Oral Tablet
33 A Randomized, Prospective Multicenter Study to Determine the Incidence of Atrial Fibrillation and Heart Failure in Correlation to Stimulation Modes of Pacemakers Unknown status NCT00161551 Phase 4
34 Comparison of Anti-inflammatory Effects of Rivaroxaban Versus Dabigatran in Patients With Non-valvular Atrial Fibrillation (RIVAL-AF Study) -Multicenter Randomized Study- Unknown status NCT02331602 Phase 4 Rivaroxaban;Dabigatran
35 The Study of Rosuvastatin for Reduction of Postoperative Paroxysmal Atrial Fibrillation in Patient Undergoing Radiofrequency Catheter Ablation Unknown status NCT02502110 Phase 4 rosuvastatin
36 PV-Isolation for Paroxysmal Atrial Fibrillation: Isolation of the Arrhythmogenic Vein(s) vs. Isolation of All Veins Unknown status NCT00605748 Phase 4
37 Test of Efficacy and Safety of the Dual Antiplatelet Therapy Compared to the Combination of Oral Anticoagulant Therapy + Dual Antiplatelet Therapy in Patients With Atrial Fibrillation With Low-moderate Risk Submitted to Coronary Stent Implantation Unknown status NCT01141153 Phase 4 Acetylsalicylic Acid + clopidogrel + acenocoumarol;Acetylsalicylic Acid + clopidogrel
38 The Danish Non-vitamin K Antagonist Oral Anticoagulation Study. A Cluster Randomized Study Comparing Safety and Efficacy of Edoxaban, Apixaban, Rivaroxaban and Dabigatran for Oral Anticoagulation in Atrial Fibrillation (DANNOAC-AF). Unknown status NCT03129490 Phase 4 Dabigatran Etexilate Oral Capsule;Rivaroxaban Oral Tablet;Edoxaban Oral Tablet;Apixaban Oral Tablet
39 A Randomized Study Comparing Dabigatran Etexilate Versus Warfarin in Chinese Patients With Nonvalvular Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention With Stenting (DES) Unknown status NCT03536611 Phase 4 dabigatran;warfarin
40 Pulmonary Vein Isolation With Versus Without Continued Antiarrhythmic Drug Treatment in Subjects With Recurrent Atrial Fibrillation: A Prospective 2-Centre Randomized Controlled Clinical Study (POWDER-AF) Unknown status NCT02475642 Phase 4
41 Linear Anatomically Versus Focal Electrophysiologically Guided Substrate Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196157 Phase 4
42 Randomized Study Comparing Cardioversion vs. Catheter Ablation in Patients With Persistent Atrial Fibrillation Unknown status NCT00196209 Phase 4
43 A Randomized, Prospective Multicenter Pilot Study to Determine the Influence of the Ventricular Pacing Site on the Incidence of Atrial Fibrillation and Heart Failure in Patients With Indication for Permanent Pacemaker Stimulation Therapy. Unknown status NCT00292383 Phase 4
44 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
45 The Use of Dabigatran Etexilate in Patients With Atrial Fibrillation After Mitral Valve Prosthetic Replacement Unknown status NCT03183843 Phase 4 Dabigatran Etexilate;Warfarin
46 Catheter Ablation for Atrial Fibrillation: A Multicenter Clinical Trial Unknown status NCT01113294 Phase 4
47 Dronedarone in Pacemaker Patients With Paroxysmal Atrial Fibrillation Unknown status NCT01070667 Phase 4 Dronedarone;Placebo
48 Impact of Irbesartan on Oxidative Stress and C-Reactive Protein Levels in Patients With Persistent Atrial Fibrillation Unknown status NCT00613496 Phase 4 irbesartan;placebo
49 Comparison Between "Conventional Monitoring" Versus "Monitoring Via Vitaphone" in the Detection of Post Ablation Atrial Arrhythmias of Paroxysmal Atrial Fibrillation Unknown status NCT03966976 Phase 4
50 Atrial Fibrillation Therapy: A Multi-Center Clinical Study Unknown status NCT01341353 Phase 4 Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists

Search NIH Clinical Center for Familial Atrial Fibrillation

Inferred drug relations via UMLS 71 / NDF-RT 50 :


anisindione
Atenolol
Deslanoside
Digitalis preparation
DIGITALIS,POWDERED
Digitoxin
Digoxin
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
Disopyramide
Disopyramide Phosphate
DITIAZ
dofetilide
ibutilide
ibutilide fumarate
Metoprolol
metoprolol succinate
Metoprolol Tartrate
Procainamide
Procainamide Hydrochloride
Propafenone
Propafenone Hydrochloride
Quinidine
quinidine gluconate
quinidine polygalacturonate
Quinidine Sulfate
Sotalol
Sotalol Hydrochloride
Verapamil
Verapamil hydrochloride
Warfarin
Warfarin Sodium
WARFARIN SODIUM ISOPROPANOL COMPLEX

Genetic Tests for Familial Atrial Fibrillation

Genetic tests related to Familial Atrial Fibrillation:

# Genetic test Affiliating Genes
1 Familial Atrial Fibrillation 28

Anatomical Context for Familial Atrial Fibrillation

Organs/tissues related to Familial Atrial Fibrillation:

MalaCards : Heart, Atrioventricular Node, Brain, Lung, Kidney, Spinal Cord, Endothelial

Publications for Familial Atrial Fibrillation

Articles related to Familial Atrial Fibrillation:

(show top 50) (show all 1072)
# Title Authors PMID Year
1
A mutation in the atrial-specific myosin light chain gene (MYL4) causes familial atrial fibrillation. 62 5
27066836 2016
2
A novel SCN5A gain-of-function mutation M1875T associated with familial atrial fibrillation. 53 62
18929244 2008
3
Cardiac sodium channel mutation in atrial fibrillation. 53 62
18088563 2008
4
Human KCNQ1 S140G mutation is associated with atrioventricular blocks. 53 62
17467630 2007
5
Atrial fibrillation in KCNE1-null mice. 53 62
15947250 2005
6
Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. 53 62
15368194 2004
7
KCNQ1 gain-of-function mutation in familial atrial fibrillation. 53 62
12522251 2003
8
Strength of association of classical vascular risk factors in young patients with ischaemic stroke: a case-control study. 62
36309160 2022
9
bZIP transcription factors PcYap1 and PcRsmA link oxidative stress response to secondary metabolism and development in Penicillium chrysogenum. 62
35366869 2022
10
Variable Clinical Appearance of the Kir2.1 Rare Variants in Russian Patients with Long QT Syndrome. 62
35456365 2022
11
Natriuretic Peptide Oligomers Cause Proarrhythmic Metabolic and Electrophysiological Effects in Atrial Myocytes. 62
35212578 2022
12
Functional analysis of the bZIP-type transcription factors AtfA and AtfB in Aspergillus nidulans. 62
36204617 2022
13
Whole-Exome Sequencing Implicates Neuronal Calcium Channel with Familial Atrial Fibrillation. 62
35154276 2022
14
A novel PRRX1 loss-of-function variation contributing to familial atrial fibrillation and congenital patent ductus arteriosus. 62
35377386 2022
15
PRRX1 Loss-of-Function Mutations Underlying Familial Atrial Fibrillation. 62
34845933 2021
16
Zfhx3 Transcription Factor Represses the Expression of SCN5A Gene and Decreases Sodium Current Density (INa). 62
34884836 2021
17
Epistatic interaction of PDE4DIP and DES mutations in familial atrial fibrillation with slow conduction. 62
34289528 2021
18
Familial atrial rapid fibrillation associated with double mutations of SCN5A and KCNQ1. 62
33632346 2021
19
8-hydroxypinoresinol-4-O-β-D-glucoside from Valeriana officinalis L. Is a Novel Kv1.5 Channel Blocker. 62
33932511 2021
20
Human induced pluripotent stem cell-derived atrial cardiomyocytes carrying an SCN5A mutation identify nitric oxide signaling as a mediator of atrial fibrillation. 62
34019817 2021
21
The Regulatory Mechanism of Water Activities on Aflatoxins Biosynthesis and Conidia Development, and Transcription Factor AtfB Is Involved in This Regulation. 62
34205815 2021
22
Connexin45 (GJC1) loss-of-function mutation contributes to familial atrial fibrillation and conduction disease. 62
33429106 2021
23
The inhibitory mechanism of methyl jasmonate on Aspergillus flavus growth and aflatoxin biosynthesis and two novel transcription factors are involved in this action. 62
33648276 2021
24
Molecular Pathology of Sodium Channel Beta-Subunit Variants. 62
34867379 2021
25
Proteinuria versus albuminuria in 24-hour urine collection: prevalence and clinical outcome in non-hypoxemic adult patients with congenital heart disease. 62
33815919 2021
26
Citrate pretreatment attenuates hypoxia/reoxygenation-induced cardiomyocyte injury via regulating microRNA-142-3p/Rac1 aix. 62
32456513 2020
27
ISL1 loss-of-function variation causes familial atrial fibrillation. 62
32771629 2020
28
Clinical profile and outcome of familial versus non-familial atrial fibrillation. 62
32273045 2020
29
Generation of patient-specific induced pluripotent stem cells (ZZUSAHi001-A) derived from a familial atrial fibrillation patient carrying KCNA5 c.775G>A mutation. 62
32721895 2020
30
[Effectiveness, safety and costs of stroke prevention in non-valvular auricular fibrillation. Study of cohorts matched by Propensity score]. 62
31551166 2020
31
The Genetic Puzzle of Familial Atrial Fibrillation. 62
32118049 2020
32
Putative role of Brugada syndrome genes in familial atrial fibrillation. 62
31539150 2019
33
Quality of life, adherence and satisfaction of patients with auricular fibrillation treated with dabigatran or vitamin K antagonists. 62
30894251 2019
34
The anti-aflatoxigenic mechanism of cinnamaldehyde in Aspergillus flavus. 62
31324857 2019
35
Electrophysiologic and molecular mechanisms of a frameshift NPPA mutation linked with familial atrial fibrillation. 62
31077706 2019
36
Characterization and haplotype study of 6 novel STR markers related to the KCNQ1 gene in heterogeneous cardiovascular disorders in the Iranian population 62
30866607 2019
37
A Novel PITX2c Gain-of-Function Mutation, p.Met207Val, in Patients With Familial Atrial Fibrillation. 62
30558760 2019
38
Survival With Auricular Fibrillation: The View From a Century Ago at the Mayo Clinic. 62
30899915 2019
39
Proarrhythmia in the p.Met207Val PITX2c-Linked Familial Atrial Fibrillation-Insights From Modeling. 62
31695623 2019
40
[Quality of care and safety indicators in anticoagulated patients with non-valvular auricular fibrillation and deep venous thromboembolic disease]. 62
29566997 2018
41
Molecular Insights into the Short QT Syndrome. 62
31355049 2018
42
A SHOX2 loss-of-function mutation underlying familial atrial fibrillation. 62
30443179 2018
43
Piperine inhibits aflatoxin B1 production in Aspergillus flavus by modulating fungal oxidative stress response. 62
28830793 2017
44
[Use of non-vitamin K antagonist oral anticoagulants in Primary Care: ACTUA study]. 62
28029563 2017
45
The Fungal bZIP Transcription Factor AtfB Controls Virulence-Associated Processes in Aspergillus parasiticus. 62
28926946 2017
46
Characteristics and temporal pattern of readmissions of patients with atrial fibrillation hospitalized in medical departments. 62
28460719 2017
47
Chronic kidney disease in hypertensive subjects ≥60 years treated in Primary Care. 62
28750875 2017
48
Familial clustering of atrial fibrillation and comparative longitudinal outcomes of familial and non-familial atrial fibrillation. 62
28485191 2017
49
Generation and cardiac subtype-specific differentiation of PITX2-deficient human iPS cell lines for exploring familial atrial fibrillation. 62
28677534 2017
50
Genome-wide transcriptome analysis of Aspergillus fumigatus exposed to osmotic stress reveals regulators of osmotic and cell wall stresses that are SakAHOG1 and MpkC dependent. 62
27706915 2017

Variations for Familial Atrial Fibrillation

ClinVar genetic disease variations for Familial Atrial Fibrillation:

5 (show top 50) (show all 70)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MYL4 NM_002476.2(MYL4):c.31G>A (p.Glu11Lys) SNV Pathogenic
224067 rs886037778 GRCh37: 17:45286819-45286819
GRCh38: 17:47209453-47209453
2 KCNJ2 NM_000891.3(KCNJ2):c.*2776del DEL Uncertain Significance
324885 rs886053343 GRCh37: 17:68175240-68175240
GRCh38: 17:70179099-70179099
3 KCNJ2 NM_000891.3(KCNJ2):c.*1721dup DUP Uncertain Significance
324865 rs35753731 GRCh37: 17:68174168-68174169
GRCh38: 17:70178027-70178028
4 KCNJ2 NM_000891.3(KCNJ2):c.*324del DEL Uncertain Significance
324839 rs570173316 GRCh37: 17:68172786-68172786
GRCh38: 17:70176645-70176645
5 KCNJ2 NM_000891.3(KCNJ2):c.*3391_*3392dup DUP Uncertain Significance
324894 rs552636156 GRCh37: 17:68175852-68175853
GRCh38: 17:70179711-70179712
6 KCNJ2 NM_000891.3(KCNJ2):c.*2875_*2876del DEL Uncertain Significance
324887 rs561353262 GRCh37: 17:68175339-68175340
GRCh38: 17:70179198-70179199
7 KCNJ2 NM_000891.3(KCNJ2):c.*2771_*2775del DEL Uncertain Significance
324882 rs35656864 GRCh37: 17:68175206-68175210
GRCh38: 17:70179065-70179069
8 KCNJ2 NM_000891.3(KCNJ2):c.*1702CT[3] MICROSAT Uncertain Significance
324864 rs1555604187 GRCh37: 17:68174165-68174166
GRCh38: 17:70178024-70178025
9 KCNJ2 NM_000891.3(KCNJ2):c.*2775dup DUP Uncertain Significance
324879 rs35656864 GRCh37: 17:68175205-68175206
GRCh38: 17:70179064-70179065
10 KCNJ2 NM_000891.3(KCNJ2):c.-88C>T SNV Uncertain Significance
324828 rs886053322 GRCh37: 17:68171093-68171093
GRCh38: 17:70174952-70174952
11 KCNJ2 NM_000891.3(KCNJ2):c.*1719_*1721dup DUP Uncertain Significance
324867 rs35753731 GRCh37: 17:68174168-68174169
GRCh38: 17:70178027-70178028
12 ABCC9 NM_020297.4(ABCC9):c.4316-14T>G SNV Uncertain Significance
308032 rs886049168 GRCh37: 12:21960427-21960427
GRCh38: 12:21807493-21807493
13 GJA5 NM_181703.4(GJA5):c.*1211A>G SNV Uncertain Significance
292438 rs886045244 GRCh37: 1:147229084-147229084
GRCh38: 1:147756951-147756951
14 KCNJ2 NM_000891.3(KCNJ2):c.*2774_*2775del DEL Uncertain Significance
324880 rs35656864 GRCh37: 17:68175206-68175207
GRCh38: 17:70179065-70179066
15 KCNJ2 NM_000891.3(KCNJ2):c.*2772_*2775del DEL Uncertain Significance
324881 rs35656864 GRCh37: 17:68175206-68175209
GRCh38: 17:70179065-70179068
16 KCNJ2 NM_000891.3(KCNJ2):c.*1702dup DUP Uncertain Significance
324863 rs886053334 GRCh37: 17:68174165-68174166
GRCh38: 17:70178024-70178025
17 KCNJ2 NM_000891.3(KCNJ2):c.*1702_*1704dup DUP Uncertain Significance
324862 rs1555604193 GRCh37: 17:68174165-68174166
GRCh38: 17:70178024-70178025
18 KCNJ2 NM_000891.3(KCNJ2):c.*2770_*2775del DEL Uncertain Significance
324883 rs35656864 GRCh37: 17:68175206-68175211
GRCh38: 17:70179065-70179070
19 ABCC9 NM_020297.4(ABCC9):c.2238-16del DEL Uncertain Significance
308036 rs886049170 GRCh37: 12:22016004-22016004
GRCh38: 12:21863070-21863070
20 KCNJ2 NM_000891.3(KCNJ2):c.-162delinsTCAGAGTAGT INDEL Uncertain Significance
324827 rs376713253 GRCh37: 17:68171019-68171019
GRCh38: 17:70174878-70174878
21 KCNJ2 NM_000891.3(KCNJ2):c.*1128dup DUP Uncertain Significance
324851 rs777658732 GRCh37: 17:68173591-68173592
GRCh38: 17:70177450-70177451
22 GJA5 NM_181703.4(GJA5):c.*1259C>T SNV Uncertain Significance
292437 rs886045243 GRCh37: 1:147229036-147229036
GRCh38: 1:147756903-147756903
23 KCNJ2 NM_000891.3(KCNJ2):c.*1720_*1721dup DUP Uncertain Significance
324866 rs35753731 GRCh37: 17:68174168-68174169
GRCh38: 17:70178027-70178028
24 ABCC9 NM_020297.4(ABCC9):c.1165-4del DEL Uncertain Significance
308042 rs886049172 GRCh37: 12:22063250-22063250
GRCh38: 12:21910316-21910316
25 KCNJ2 NM_000891.3(KCNJ2):c.*3463del DEL Uncertain Significance
324895 rs3841509 GRCh37: 17:68175918-68175918
GRCh38: 17:70179777-70179777
26 ABCC9 NM_020297.4(ABCC9):c.1165-7_1165-6del DEL Uncertain Significance
308043 rs35857705 GRCh37: 12:22063252-22063253
GRCh38: 12:21910318-21910319
27 ABCC9 NM_020297.4(ABCC9):c.1165-6dup DUP Uncertain Significance
45385 rs35857705 GRCh37: 12:22063251-22063252
GRCh38: 12:21910317-21910318
28 LAMA4 NM_001105206.3(LAMA4):c.3742A>G (p.Ile1248Val) SNV Uncertain Significance
488160 rs547323858 GRCh37: 6:112454047-112454047
GRCh38: 6:112132845-112132845
29 KCNE2 NM_172201.2(KCNE2):c.-121C>T SNV Uncertain Significance
339713 rs188625398 GRCh37: 21:35736342-35736342
GRCh38: 21:34364043-34364043
30 KCNQ1 NM_000218.3(KCNQ1):c.66C>T (p.Gly22=) SNV Uncertain Significance
304215 rs886048162 GRCh37: 11:2466394-2466394
GRCh38: 11:2445164-2445164
31 KCNQ1 NM_000218.3(KCNQ1):c.650C>T (p.Ser217Phe) SNV Uncertain Significance
304217 rs886048163 GRCh37: 11:2592600-2592600
GRCh38: 11:2571370-2571370
32 KCNQ1-AS1, KCNQ1 NM_000218.3(KCNQ1):c.*292C>A SNV Uncertain Significance
304240 rs886048169 GRCh37: 11:2869525-2869525
GRCh38: 11:2848295-2848295
33 KCNQ1 NM_000218.3(KCNQ1):c.29C>A (p.Ala10Asp) SNV Uncertain Significance
304214 rs886048161 GRCh37: 11:2466357-2466357
GRCh38: 11:2445127-2445127
34 KCNQ1-AS1, KCNQ1 NM_000218.3(KCNQ1):c.*897G>T SNV Uncertain Significance
304266 rs561861522 GRCh37: 11:2870130-2870130
GRCh38: 11:2848900-2848900
35 KCNQ1OT1, KCNQ1 NM_000218.3(KCNQ1):c.1514+3G>A SNV Uncertain Significance
304226 rs374767819 GRCh37: 11:2683314-2683314
GRCh38: 11:2662084-2662084
36 KCNQ1 NM_000218.3(KCNQ1):c.781-6G>T SNV Uncertain Significance
304218 rs886048164 GRCh37: 11:2594070-2594070
GRCh38: 11:2572840-2572840
37 KCNQ1-AS1, KCNQ1 NM_000218.3(KCNQ1):c.*887_*889del DEL Uncertain Significance
304264 rs886048175 GRCh37: 11:2870119-2870121
GRCh38: 11:2848889-2848891
38 KCNQ1-AS1, KCNQ1 NM_000218.3(KCNQ1):c.1979C>A (p.Pro660His) SNV Uncertain Significance
304231 rs886048165 GRCh37: 11:2869181-2869181
GRCh38: 11:2847951-2847951
39 KCNQ1-AS1, KCNQ1 NM_000218.3(KCNQ1):c.*398C>T SNV Uncertain Significance
304246 rs886048170 GRCh37: 11:2869631-2869631
GRCh38: 11:2848401-2848401
40 KCNQ1-AS1, KCNQ1 NM_000218.3(KCNQ1):c.*160C>A SNV Uncertain Significance
304234 rs886048167 GRCh37: 11:2869393-2869393
GRCh38: 11:2848163-2848163
41 KCNQ1-AS1, KCNQ1 NM_000218.3(KCNQ1):c.*554T>G SNV Uncertain Significance
304252 rs886048172 GRCh37: 11:2869787-2869787
GRCh38: 11:2848557-2848557
42 KCNQ1 NM_000218.3(KCNQ1):c.1251+13C>T SNV Uncertain Significance
304220 rs201364493 GRCh37: 11:2608935-2608935
GRCh38: 11:2587705-2587705
43 KCNQ1-AS1, KCNQ1 NM_000218.3(KCNQ1):c.1973C>A (p.Thr658Asn) SNV Uncertain Significance
304230 rs377661455 GRCh37: 11:2869175-2869175
GRCh38: 11:2847945-2847945
44 KCNQ1-AS1, KCNQ1 NM_000218.3(KCNQ1):c.*26C>A SNV Uncertain Significance
304232 rs886048166 GRCh37: 11:2869259-2869259
GRCh38: 11:2848029-2848029
45 KCNQ1 NM_000218.3(KCNQ1):c.1355G>A (p.Arg452Gln) SNV Uncertain Significance
67030 rs145229963 GRCh37: 11:2610046-2610046
GRCh38: 11:2588816-2588816
46 KCNQ1 NM_000218.3(KCNQ1):c.1189C>T (p.Arg397Trp) SNV Uncertain Significance
52970 rs199472776 GRCh37: 11:2608860-2608860
GRCh38: 11:2587630-2587630
47 GJA5 NM_005266.7(GJA5):c.-67G>A SNV Uncertain Significance
292457 rs36214923 GRCh37: 1:147245389-147245389
GRCh38: 1:147773285-147773285
48 KCNJ2 NM_000891.3(KCNJ2):c.1259C>T (p.Pro420Leu) SNV Uncertain Significance
264482 rs749707062 GRCh37: 17:68172439-68172439
GRCh38: 17:70176298-70176298
49 GJA5 NM_005266.6(GJA5):c.-152G= SNV Likely Benign
368828 rs791286 GRCh37: 1:147245474-147245474
GRCh38: 1:147773370-147773370
50 KCNQ1OT1, KCNQ1 NM_000218.3(KCNQ1):c.1393+21538C>T SNV Likely Benign
304222 rs72850203 GRCh37: 11:2631622-2631622
GRCh38: 11:2610392-2610392

Expression for Familial Atrial Fibrillation

Search GEO for disease gene expression data for Familial Atrial Fibrillation.

Pathways for Familial Atrial Fibrillation



Pathways directly related to Familial Atrial Fibrillation:

# Pathway Source
1 Defective ABCC9 causes CMD10, ATFB12 and Cantu syndrome Reactome 66

Pathways related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.47 SCN5A SCN4B SCN3B SCN2B NPPA NKX2-5
2
Show member pathways
12.45 SCN5A SCN4B SCN3B SCN2B
3 12.18 KCNQ1 KCNJ2 KCNE2 KCNA5
4
Show member pathways
12.09 SCN5A SCN4B SCN3B SCN2B
5 11.98 SCN5A SCN4B SCN3B KCNQ1
6
Show member pathways
11.86 SCN4B SCN2B KCNJ2
7 11.4 SCN5A NKX2-5 GATA4
8 11.35 MYL4 GATA6 GATA4
9 11.34 GATA4 GATA6 NKX2-5 PITX2
10 11.09 SCN5A SCN4B SCN3B SCN2B
11 11.02 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
12 10.99 SCN4B SCN3B SCN2B
13 10.95 NPPA NKX2-5 GATA4
14 10.95 SCN5A SCN4B SCN3B SCN2B
15 10.76 NPPA NKX2-5 GATA4
16 10.65 KCNQ1 KCNJ2
17 10.28 NPPA NKX2-5 GATA4

GO Terms for Familial Atrial Fibrillation

Cellular components related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated potassium channel complex GO:0008076 9.76 KCNQ1 KCNJ2 KCNE2 KCNA5
2 T-tubule GO:0030315 9.73 SCN5A SCN2B KCNJ2
3 voltage-gated sodium channel complex GO:0001518 9.56 SCN5A SCN4B SCN3B SCN2B
4 potassium channel complex GO:0034705 9.5 KCNQ1 KCNA5
5 intercalated disc GO:0014704 9.32 SCN5A SCN4B KCNJ2 KCNA5 GJA5

Biological processes related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 49)
# Name GO ID Score Top Affiliating Genes
1 potassium ion transmembrane transport GO:0071805 10.28 KCNA5 KCNE2 KCNJ2 KCNQ1
2 sodium ion transmembrane transport GO:0035725 10.26 SCN5A SCN4B SCN3B SCN2B
3 potassium ion transport GO:0006813 10.19 KCNQ1 KCNJ2 KCNE2 KCNA5 GJA5
4 sodium ion transport GO:0006814 10.18 KCNQ1 SCN2B SCN3B SCN4B SCN5A
5 cell fate commitment GO:0045165 10.17 GATA6 GATA5 GATA4
6 aortic valve morphogenesis GO:0003180 10.17 NPPA NKX2-5 GATA5 GATA4
7 potassium ion import across plasma membrane GO:1990573 10.15 KCNQ1 KCNJ2 KCNE2
8 heart development GO:0007507 10.13 GATA4 GATA5 GJA5 KCNQ1 NKX2-5
9 monoatomic ion transport GO:0006811 10.13 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2
10 positive regulation of heart rate GO:0010460 10.12 SCN3B NPPA KCNQ1
11 regulation of sodium ion transmembrane transporter activity GO:2000649 10.11 SCN4B SCN3B SCN2B
12 cardiac conduction system development GO:0003161 10.11 GJA5 NKX2-5 NPPA SCN5A
13 potassium ion export across plasma membrane GO:0097623 10.1 KCNQ1 KCNE2 KCNA5
14 regulation of cardiac muscle cell contraction GO:0086004 10.1 GATA4 KCNJ2 SCN5A
15 ventricular cardiac muscle cell action potential GO:0086005 10.1 SCN5A SCN3B KCNQ1 KCNE2
16 regulation of ventricular cardiac muscle cell membrane repolarization GO:0060307 10.1 GJA5 KCNE2 KCNQ1 SCN4B SCN5A
17 membrane repolarization during ventricular cardiac muscle cell action potential GO:0098915 10.09 KCNE2 KCNQ1 SCN2B
18 regulation of membrane repolarization GO:0060306 10.09 KCNQ1 KCNJ2 KCNE2
19 anatomical structure morphogenesis GO:0009653 10.08 PITX2 GATA6 GATA5 GATA4
20 membrane repolarization during action potential GO:0086011 10.08 KCNQ1 KCNJ2 KCNE2
21 intestinal epithelial cell differentiation GO:0060575 10.08 GATA6 GATA5 GATA4
22 positive regulation of sodium ion transport GO:0010765 10.08 SCN5A SCN4B SCN3B NKX2-5
23 membrane depolarization during cardiac muscle cell action potential GO:0086012 10.07 SCN5A SCN4B SCN3B SCN2B KCNJ2
24 regulation of atrial cardiac muscle cell membrane depolarization GO:0060371 10.06 GJA5 SCN2B SCN3B SCN5A
25 cardiac muscle cell differentiation GO:0055007 10.04 NKX2-5 GATA6 GATA4
26 regulation of ventricular cardiac muscle cell membrane depolarization GO:0060373 10.03 SCN5A SCN3B GJA5
27 regulation of atrial cardiac muscle cell membrane repolarization GO:0060372 10.03 SCN5A NPPA KCNQ1 KCNA5
28 atrioventricular node development GO:0003162 10.02 GATA4 GATA6 NKX2-5
29 regulation of monoatomic ion transmembrane transport GO:0034765 10.02 KCNA5 KCNE2 KCNJ2 KCNQ1 SCN2B SCN3B
30 positive regulation of cardioblast differentiation GO:0051891 10.01 GATA4 GATA6 NKX2-5
31 atrial septum morphogenesis GO:0060413 10 NKX2-5 GATA4
32 atrioventricular canal development GO:0036302 10 GATA6 GATA4
33 cardiac muscle contraction GO:0060048 10 KCNQ1 MYL4 NKX2-5 SCN2B SCN3B SCN4B
34 membrane repolarization during cardiac muscle cell action potential GO:0086013 9.99 KCNJ2 KCNQ1
35 positive regulation of cardiac muscle contraction GO:0060452 9.99 NPPA KCNQ1
36 membrane repolarization during atrial cardiac muscle cell action potential GO:0098914 9.97 KCNQ1 KCNA5
37 SA node cell action potential GO:0086015 9.97 SCN5A SCN3B
38 embryonic heart tube left/right pattern formation GO:0060971 9.96 PITX2 NKX2-5
39 AV node cell action potential GO:0086016 9.96 SCN5A SCN4B
40 atrial cardiac muscle cell action potential GO:0086014 9.96 SCN5A SCN3B NUP155 KCNQ1 KCNA5
41 cardiac muscle tissue development GO:0048738 9.94 NKX2-5 GATA6 GATA5
42 negative regulation of delayed rectifier potassium channel activity GO:1902260 9.88 KCNQ1 KCNE2
43 membrane repolarization GO:0086009 9.88 KCNQ1 KCNE2
44 cardiac ventricle morphogenesis GO:0003208 9.87 GATA4 NKX2-5
45 cardiac conduction GO:0061337 9.76 SCN3B SCN2B KCNQ1
46 cardiac muscle cell action potential involved in contraction GO:0086002 9.73 SCN5A SCN4B SCN3B SCN2B KCNJ2 KCNE2
47 system development GO:0048731 9.7 GATA6 GATA4
48 negative regulation of voltage-gated potassium channel activity GO:1903817 9.68 KCNQ1 KCNE2
49 regulation of heart rate by cardiac conduction GO:0086091 9.53 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2

Molecular functions related to Familial Atrial Fibrillation according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 transcription cis-regulatory region binding GO:0000976 10.16 PITX2 NKX2-5 GATA6 GATA5 GATA4
2 RNA polymerase II-specific DNA-binding transcription factor binding GO:0061629 10.1 PITX2 NKX2-5 GATA6 GATA4
3 scaffold protein binding GO:0097110 10.04 SCN5A KCNQ1 KCNA5
4 transmembrane transporter binding GO:0044325 10.02 SCN5A SCN4B SCN3B KCNQ1 KCNE2
5 voltage-gated potassium channel activity GO:0005249 9.93 KCNQ1 KCNE2 KCNA5
6 delayed rectifier potassium channel activity GO:0005251 9.91 KCNA5 KCNE2 KCNQ1
7 sodium channel regulator activity GO:0017080 9.88 SCN4B SCN3B SCN2B
8 voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarization GO:0086008 9.81 KCNJ2 KCNQ1
9 NFAT protein binding GO:0051525 9.8 GATA6 GATA4
10 voltage-gated potassium channel activity involved in atrial cardiac muscle cell action potential repolarization GO:0086089 9.78 KCNQ1 KCNA5
11 voltage-gated sodium channel activity GO:0005248 9.77 SCN5A SCN4B SCN2B
12 voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization GO:1902282 9.73 KCNE2 KCNQ1 SCN2B
13 cis-regulatory region sequence-specific DNA binding GO:0000987 9.72 GATA6 GATA5 GATA4
14 potassium channel activity GO:0005267 9.7 KCNQ1 KCNE2 KCNA5
15 voltage-gated sodium channel activity involved in cardiac muscle cell action potential GO:0086006 9.56 SCN5A SCN4B SCN3B SCN2B
16 sodium channel activity GO:0005272 9.46 SCN5A SCN4B SCN3B SCN2B
17 voltage-gated monoatomic ion channel activity GO:0005244 9.36 SCN5A SCN4B SCN3B SCN2B KCNQ1 KCNJ2

Sources for Familial Atrial Fibrillation

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....